Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2
Sylwia Ammoun(University of Plymouth), C. Oliver Hanemann(University of Plymouth)
Cited by 54
Related Papers
Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation
|Genetics in Medicine|2021|766
Peripheral myelin protein–22 gene maps in the duplication in chromosome 17p11.2 associated with Charcot–Marie–Tooth 1A
|Nature Genetics|1992|294
GATA-4, a potential novel therapeutic target for high-grade meningioma, regulates miR-497, a potential novel circulating biomarker for high-grade meningioma
|EBioMedicine|2020|41